Difference between revisions of "Part:BBa K3606003"
 
(19 intermediate revisions by 2 users not shown)
Line 5: Line 5:
 
This part produces an antibiotic originated from Escherichia coli that targets a bacterial topoisomerase, DNA gyrase.
 
This part produces an antibiotic originated from Escherichia coli that targets a bacterial topoisomerase, DNA gyrase.
  
 +
<h2>Background:</h2>
 +
Here, we tried to improve the former antimicrobial peptide(mccb17) expressing system of 2019 Fudan [[BBa_K3245010]]. By dividing into the peptide expressing parts and the immunity parts, we wanted to firstly test whether the polycistron could work properly and separately, then
 +
manipulate their expression level with more efficiency.
 +
 +
<h2>Design:</h2>
 +
This part is an antibiotic coding gene cluster with leader peptide and proteins for its maturation.
 +
 +
https://2020.igem.org/wiki/images/b/b4/T--Fudan--img_mcbabcd.png
 +
 +
Figure1. structure of mcbABCD
 +
 +
<h2>Results</h2>
 +
We have successfully expressed mcbA and mcb C for the fundamental validation of the antimicrobial peptide(mccb17) expression.
 +
We've constructed the plasmid for mcbB and mcbD expression, yet the results of colony PCR is false positive thus further validation is needed.
 +
https://2020.igem.org/wiki/images/f/f3/T--Fudan--Poster_Mcb-gels.jpg
 +
Figure2. gel map for mcbA, mcbC, mcbE and mcbF
  
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here
−
===Usage and Biology===
+
<h2>Usage and Biology:</h2>
 +
We introduced it to our improved antibiotic expressing system to inhibit the growth of other bacteria in human intestine so as to enhance Nissle's competitiveness, as well as to reduce risk of illness caused by some opportunistic pathogens.
  
 
<!-- -->
 
<!-- -->
Line 13: Line 30:
 
<partinfo>BBa_K3606003 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K3606003 SequenceAndFeatures</partinfo>
  
 +
<h2>Further Application</h2>
 +
For futher application, this part is provided as an antimicrobial peptide(mccb17) expressing example and are effective for a wide range of microbes. This part can be used together with [[BBa_K3606004]] to provide immunity for the engineered strain and create survival advantage. These part are especially useful to be expressed in vivo because research has proved that it can also ease the inflammation in intestine by limiting the expansion of related pathogens and pathobionts.
  
 
<!-- Uncomment this to enable Functional Parameter display  
 
<!-- Uncomment this to enable Functional Parameter display  
Line 18: Line 37:
 
<partinfo>BBa_K3606003 parameters</partinfo>
 
<partinfo>BBa_K3606003 parameters</partinfo>
 
<!-- -->
 
<!-- -->
 +
<h2>Reference</h2>
 +
<p>[1] Collin F, Maxwell A. The Microbial Toxin Microcin B17: Prospects for the Development of New Antibacterial Agents. J Mol Biol. 2019;431(18):3400–3426. doi:10.1016/j.jmb.2019.05.050</p>
 +
<p>[2] S. Duquesne, D. Destoumieux-Garzón, J. Peduzzi, S. Rebuffat. Microcins, gene-encoded antibacterial peptides from enterobacteria</p>
 +
<p>[3] Sassone-Corsi M, Nuccio SP, Liu H, Hernandez D, Vu CT, Takahashi AA, Edwards RA, Raffatellu M. Microcins mediate competition among Enterobacteriaceae in the inflamed gut. Nature. 2016 Dec 8;540(7632):280-283.

Latest revision as of 02:34, 5 December 2020


mcbABCD

This part produces an antibiotic originated from Escherichia coli that targets a bacterial topoisomerase, DNA gyrase.

Background:

Here, we tried to improve the former antimicrobial peptide(mccb17) expressing system of 2019 Fudan BBa_K3245010. By dividing into the peptide expressing parts and the immunity parts, we wanted to firstly test whether the polycistron could work properly and separately, then manipulate their expression level with more efficiency.

Design:

This part is an antibiotic coding gene cluster with leader peptide and proteins for its maturation.

T--Fudan--img_mcbabcd.png

Figure1. structure of mcbABCD

Results

We have successfully expressed mcbA and mcb C for the fundamental validation of the antimicrobial peptide(mccb17) expression. We've constructed the plasmid for mcbB and mcbD expression, yet the results of colony PCR is false positive thus further validation is needed. T--Fudan--Poster_Mcb-gels.jpg Figure2. gel map for mcbA, mcbC, mcbE and mcbF


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Unknown
  • 12
    INCOMPATIBLE WITH RFC[12]
    Unknown
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal PstI site found at 2297
    Illegal PstI site found at 2330
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal PstI site found at 2297
    Illegal PstI site found at 2330
    Illegal NgoMIV site found at 1959
    Illegal AgeI site found at 2131
  • 1000
    COMPATIBLE WITH RFC[1000]

Further Application

For futher application, this part is provided as an antimicrobial peptide(mccb17) expressing example and are effective for a wide range of microbes. This part can be used together with BBa_K3606004 to provide immunity for the engineered strain and create survival advantage. These part are especially useful to be expressed in vivo because research has proved that it can also ease the inflammation in intestine by limiting the expansion of related pathogens and pathobionts.

Reference

[1] Collin F, Maxwell A. The Microbial Toxin Microcin B17: Prospects for the Development of New Antibacterial Agents. J Mol Biol. 2019;431(18):3400–3426. doi:10.1016/j.jmb.2019.05.050

[2] S. Duquesne, D. Destoumieux-Garzón, J. Peduzzi, S. Rebuffat. Microcins, gene-encoded antibacterial peptides from enterobacteria

[3] Sassone-Corsi M, Nuccio SP, Liu H, Hernandez D, Vu CT, Takahashi AA, Edwards RA, Raffatellu M. Microcins mediate competition among Enterobacteriaceae in the inflamed gut. Nature. 2016 Dec 8;540(7632):280-283.